Esperion Therapeutics, Inc.(ESPR)

$3.18—

Chart

Esperion Therapeutics, Inc.(ESPR)

NASDAQ

$3.18—

Chart Studio

ESPR(ESPR)

ESPR

Overview Fair Value Stream Notebook Intel Chart History Fundamentals TTM Earnings Analysts News Financials Segments Insiders Institl.DCF Peers

FY2027 EPS Estimate

$0.27

FY2027E EPS$0.27

FY2028E EPS$0.43

Analyst Sentiment

Wall St. Consensus

Hold

24 analysts·High coverage

Score

8 Buy (33%)14 Hold (58%)2 Sell (9%)

Rating Breakdown

Strong Buy

00%

Buy

833%

Hold

1458%

Sell

28%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear

$3.16

-0.6%

Consensus

$3.16

-0.6%

Bull

$3.28

+3.1%

12-Month Target Range24 analysts

$3.16$3.16$3.28

Current $3.18Consensus

Current Price

$3.18

Above Consensus

$0.02

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)

FY2027

Rev+15.79%

EPS—

FY2028

Rev+12.43%

EPS+58.28%

FY2029

Rev+30.56%

EPS+18.60%

Raw consensus estimates (low / average / high) from covering analysts.

Annual

Metric	FY2026E	FY2027E	FY2028E	FY2029E	FY2030E
Revenue Avg	$388M	$449M	$505M	$659M	$745M
Low	$357M	$395M	$370M	$546M	$617M
High	$426M	$486M	$575M	$728M	$822M
EBITDA Avg	$-219M	$-253M	$-284M	$-371M	$-420M
Low	$-240M	$-274M	$-324M	$-410M	$-464M
High	$-201M	$-223M	$-209M	$-308M	$-348M
EBIT Avg	$-219M	$-253M	$-285M	$-371M	$-420M
Low	$-240M	$-274M	$-324M	$-410M	$-464M
High	$-201M	$-223M	$-209M	$-308M	$-348M
Net Income Avg	$-8M	$58M	$121M	$106M	$139M
Low	$-9M	$51M	$-326M	$82M	$108M
High	$-6M	$64M	$326M	$120M	$158M
EPS Avg	$-0.04	$0.27	$0.43	$0.51	$0.67
Low	$-0.05	$0.25	$-1.57	$0.40	$0.52
High	$-0.03	$0.31	$1.57	$0.58	$0.76
Analysts (Rev / EPS)	1 / 2	4 / 4	3 / 3	1 / 1	2 / 1

Quarterly

Metric	Q3 2026	Q4 2026	Q1 2027	Q2 2027	Q3 2027	Q4 2027
Revenue Avg	$99M	$108M	$105M	$116M	$123M	$131M
Low	$92M	$104M	$101M	$111M	$118M	$126M
High	$103M	$110M	$108M	$118M	$126M	$134M
EBITDA Avg	$-56M	$-61M	$-59M	$-65M	$-69M	$-74M
Low	$-58M	$-62M	$-61M	$-67M	$-71M	$-76M
High	$-52M	$-58M	$-57M	$-63M	$-67M	$-71M
EBIT Avg	$-56M	$-61M	$-59M	$-65M	$-69M	$-74M
Low	$-58M	$-62M	$-61M	$-67M	$-71M	$-76M
High	$-52M	$-58M	$-57M	$-63M	$-67M	$-71M
Net Income Avg	$359,183	$5M	$8M	$14M	$17M	$22M
Low	$-359,183	$5M	$8M	$14M	$16M	$21M
High	$897,958	$5M	$9M	$15M	$17M	$22M
EPS Avg	$0.00	$0.02	$0.03	$0.06	$0.07	$0.09
Low	$-0.00	$0.02	$0.03	$0.05	$0.06	$0.08
High	$0.00	$0.02	$0.03	$0.06	$0.07	$0.09
Analysts (Rev / EPS)	2 / 2	1 / 1	1 / 1	1 / 1	1 / 1	1 / 1

Earnings Surprises

Recent Analyst Actions

May 1, 2026Jefferies

Esperion downgraded to Hold from Buy at Jefferies

Target:$3.28

+5.5%from $3.11

May 1, 2026Piper Sandler

Esperion downgraded to Neutral from Overweight at Piper Sandler

Target:$3.16

+1.6%from $3.11

May 1, 2026H.C. Wainwright

Esperion downgraded to Neutral from Buy at H.C. Wainwright

Target:$3.16

+1.5%from $3.11

May 1, 2026Cantor Fitzgerald

Esperion downgraded to Neutral from Overweight at Cantor Fitzgerald

Target:$3.16

+58.0%from $2.00

Nov 24, 2025Piper Sandler

Esperion initiated with an Overweight at Piper Sandler

Target:$9.00

+183.9%from $3.17

Sep 25, 2025Cantor Fitzgerald

Esperion price target raised to $9 from $7 at Cantor Fitzgerald

Target:$9.00

+251.6%from $2.56

Dec 17, 2024Cantor Fitzgerald

Esperion initiated with an Overweight at Cantor Fitzgerald

Target:$8.00

+163.2%from $3.04

May 4, 2022Needham

Esperion Therapeutics Rises on Upbeat Q1 Results

Target:$12.00

+83.8%from $6.53

May 4, 2021Wells Fargo

Esperion Stock Plummets On Wider Than Expected Q1 Earnings Loss; Analysts Move To Sidelines

Target:$20.00

-21.8%from $25.59

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance